Systems and computational biologists, physician-scientists, pharmacologists, biochemists and cell biologists will collaborate in a new Laboratory of Systems Pharmacology (LSP) to apply a measure-model approach to understanding the mechanisms of action of therapeutic drugs in multiple disease areas. The LSP will pioneer the development of quantitative network-centric approaches to pharmacology and toxicology that include analysis of dose-time-response relationships at a single-cell level, modeling of cellular network dynamics and their perturbation by drugs, development of pharmacokinetic and pharmacodynamic models in mouse and ultimately in man and use of systematic approaches to identify and qualify new drug targets. Our approach combines mathematical modeling with empirical measurement (including work with clinical samples and data) and aims to create quantitative and predictive drug response models at different temporal and physical scales.
We aim to reinvigorate pharmacology and toxicology as foundational disciplines of translational medicine, develop the conceptual underpinning for personalized and precision medicine and lower the cost of drug discovery by improving its predictability. Close interactions with industry and the FDA will help address the productivity gap in drug discovery and development. The LSP is innovative with respect to its goal of using problems in basic and translational pharmacology to link three disciplines (cell and molecular biology, computational biology and medicine) and its aim of advancing therapeutic science in the Boston area and beyond. Students and postdocs supervised by 18 faculty members, 2 independent postdoctoral fellows and two PhD-level staff from 7 institutions will work in immediate proximity in a new custom-designed laboratory. The lab will host a new graduate program in therapeutics and multi-factored outreach activities that will promote systems pharmacology internationally. These goals will be achieved through four inter-linked research programs (Aims 1-4), a core dedicated to efficient translation of LSP research (Aim 5), an education core and administrative/outreach activities (Aims 6-8).
Aim 1 will focus on the determinants of dose-response at a single-cell level, including the role of cell-to- cell variability in fractional response and of timing and order-of-exposure in combination therapy.
Aim 2 will take a network-level approach to understanding therapeutic, toxic and paradoxical drug responses by kinase inhibitors in three types of cancer. The mechanistic basis and consequences of poly-pharmacology will also be examined along with differential drug responsiveness by normal and diseased tissues.
Aim 3 will address PK- PD by developing multi-scale models of drug actions at the level of cells, tissues and organisms and new methods for measuring drug distribution at the cellular and subcellular levels.
Aim 4 will apply machine learning and causal reasoning to target discovery from clinical records in asthma, inflammatory disease and fibrosis and pursue a structure-guided approach to identifying regulators of undruggable targets.

Public Health Relevance

The computational biologists, physician-scientists and pharmacologists in the Laboratory of Systems Pharmacology will apply a combined measure-model approach to understanding the mechanisms of action of therapeutic drugs in multiple disease areas. They will develop and apply new tools to (i) investigate the factors that determine the therapeutic index of drugs at a single cell level and in tissues (ii) apply knowledge of cellular networks to develop a rational approach to combination therapy (iii) identify and qualify new drug targets for significant unmet medical needs. Success with our approach will advance personalized medicine and reduce the frequency of late-stage failure in drug discovery, thereby reducing the cost of new medicines.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZGM1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Harvard Medical School
United States
Zip Code
Kitsak, Maksim; Sharma, Amitabh; Menche, Jörg et al. (2016) Tissue Specificity of Human Disease Module. Sci Rep 6:35241
Mirzakhani, Hooman; Litonjua, Augusto A; McElrath, Thomas F et al. (2016) Early pregnancy vitamin D status and risk of preeclampsia. J Clin Invest 126:4702-4715
Tirosh, Itay; Izar, Benjamin; Prakadan, Sanjay M et al. (2016) Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352:189-96
DeGennaro, Christine M; Savir, Yonatan; Springer, Michael (2016) Identifying Metabolic Subpopulations from Population Level Mass Spectrometry. PLoS One 11:e0151659
Richardson, Kirill; Bennion, Owen T; Tan, Shumin et al. (2016) Temporal and intrinsic factors of rifampicin tolerance in mycobacteria. Proc Natl Acad Sci U S A 113:8302-7
Loscalzo, Joseph (2016) Adaptions to Hypoxia and Redox Stress: Essential Concepts Confounded by Misleading Terminology. Circ Res 119:511-3
Bertero, Thomas; Oldham, William M; Cottrill, Katherine A et al. (2016) Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension. J Clin Invest 126:3313-35
Zaman, Paula; Wang, Julia; Blau, Adam et al. (2016) Incorporation of heparin-binding proteins into preformed dextran sulfate-chitosan nanoparticles. Int J Nanomedicine 11:6149-6159
Jones, Douglas S; Jenney, Anne P; Swantek, Jennifer L et al. (2016) Profiling drugs for rheumatoid arthritis that inhibit synovial fibroblast activation. Nat Chem Biol :
Liu, Bing; Liu, Qian; Yang, Lei et al. (2016) Innate immune memory and homeostasis may be conferred through crosstalk between the TLR3 and TLR7 pathways. Sci Signal 9:ra70

Showing the most recent 10 out of 19 publications